摘要
白介素8(IL-8)近来被认为是一种肿瘤血管生成和促肿瘤细胞生长因子,其在肺癌中也有相当重要的作用。肺癌患者血清和肿瘤组织中的IL-8高水平可能和预后差相关。目前,肺癌细胞和炎症细胞都已被证明可以生成IL-8。而IL-8表达的分子机制主要包括核因子κB和促分裂原活化蛋白激酶通道。另外,有研究发现,IL-8的分泌活化在肺癌的治疗中是一种普遍的现象,有可能导致肺癌治疗失败和肿瘤耐药。因此,以IL-8为靶点,可能是针对肺癌的一种可替代的临床治疗手段。
Interleukin-8 (IL-8)has been proposed to play a crucial role in the angiogenesis and growth of tumor,including lung cancer. High level of IL-8 in both serum and lung cancer tissue may be correlated with the poor prognosis of disease. The secretion of IL-8 is derived from both tumor cells and inflammatory cells. The molecular mechanism of IL-8 expression might be closely associated with nuclear factor-κB and mitogen-activated protein kinase pathway. Other studies have suggested that the secretion and activation of IL-8 are common in the treatment of lung cancer, might lead to treatment failure and drug resistance of lung eancer. Thus, targeting IL-8 in lung cancer treatment might be an alternative clinical therapy.
出处
《国际呼吸杂志》
2010年第4期208-212,共5页
International Journal of Respiration
基金
上海市重点学科建设项目(B115)
复旦大学(杰出教授基金)和上海市科学技术委员会资助项目(08PJ1402900)
关键词
白介素8
趋化因子受体
肺癌
治疗
Interleukin-8
Chemokine receptor
Lung cancer
Therapy